ProCE Banner Activity

MONARCH 3 Interim OS: Abemaciclib + Nonsteroidal AI as First-line Treatment for HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Interim results from the phase III MONARCH 3 study showed a nonsignificant improvement in OS with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in patients with HR+/HER2- advanced or metastatic breast cancer.

Released: September 13, 2022

Expiration: September 12, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.